60705-96-6

Basic information

• Product Name: (2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID
• Synonyms: 2,3-dihydro-2,3-dioxo-1h-indole-1-aceticaci;2,3-dihydro-2,3-dioxo-1h-indole-1-aceticacid;2,3-dioxo-1-indolineaceticaci;2,3-dioxo-indoline-1-aceticaci;(2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)ACETIC ACID;(2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID;ISATIN-N-ACETIC ACID;CBI-BB ZERO/001450
• CAS NO: 60705-96-6
• Molecular Formula: C₁₀H₇NO₄
• Molecular Weight: 205.17
• Mol File: 60705-96-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 445.4 °C at 760 mmHg
• Flash Point: 223.2 °C
• Appearance: /
• Density: 1.522 g/cm³
• Vapor Pressure: 1.02E-08mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID(60705-96-6)
• EPA Substance Registry System: (2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID(60705-96-6)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-36
• Safety Statements: 26-45
• HazardClass: IRRITANT
• Hazardous Substances Data: 60705-96-6(Hazardous Substances Data)

Usage

General Description

(2,3-Dioxo-2,3-dihydro-indol-1-yl)-acetic acid, also known as IDA, is a compound with a chemical structure containing a indolyl ring and a carboxylic acid group. It is a synthetic organic compound that has potential applications in the field of medicine and pharmaceuticals. It is a derivative of indole, which is a heterocyclic aromatic organic compound. IDA has been studied for its potential as an anti-inflammatory and analgesic agent, and it has also been investigated for its potential to inhibit leukemia cell growth. (2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID is of interest to researchers and scientists exploring the role of indole derivatives in developing new drugs and therapeutic agents.

InChI:InChI=1/C10H7NO4/c12-8(13)5-11-7-4-2-1-3-6(7)9(14)10(11)15/h1-4H,5H2,(H,12,13)

Upstream product

• 265997-74-8 2-methyl-2-propanyl (2,3-dioxo-2,3-dihydro-1H-indol-1-yl)acetate 
• 91-56-5 indole-2,3-dione 
• 105-36-2 ethyl bromoacetate 
• 107-59-5 tert-Butyl chloroacetate 
• 105-48-6 isopropyl chloroacetate 
• 41042-21-1 (1-ethoxycarbonylmethyl)isatin 
• 41042-20-0 methyl 2-(2,3-dioxoindolin-1-yl)acetate 
• 79-11-8 chloroacetic acid 

Downstream Products

• 1402658-55-2 (3-{2-[5-(4-methoxyphenyl)-3-phenyl-4,5-dihydropyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-ylidene}-2-oxo-2,3-dihydroindol-1-yl)acetic acid 
• 1402658-73-4 {3-[5-(2-hydroxyphenyl)-3-phenylpyrazol-1-yl]-2-oxo-2,3-dihydroindol-1-yl}acetic acid 
• 1402658-79-0 {3-[5-(4-chlorophenyl)-3-phenylpyrazol-1-yl]-2-oxo-2,3-dihydroindol-1-yl}acetic acid 

Relevant articles and documents

Isatin-1,2,4-oxadiazole compound as well as preparation method and application thereof

The invention discloses an isatin-1,2,4-diazole compound and a preparation method and application thereof. The structural general formula of the isatin-1,2,4-diazole compound is shown in the specification. According to the splicing principle of drugs and the structural drug molecular design concept, a five-membered heterocyclic structure is introduced to an isatin molecular skeleton of isatin, and the isatin-1,2,4-diazole derivative is obtained. A biological activity test result shows that the isatin-1,2,4-diazole compound disclosed by the invention has good inhibitory activity on mouse mononuclear macrophage leukemia cells.

Multicomponent synthesis of novel class of isatin and 5-isatinyli-denerhodanine based diaminofuran derivatives

A simple and efficient method has been developed for the synthesis of a new collection of isatin and 5-isatinylidenerhodanine derivatives carrying furan group, from N-(carboxymethyl)isatin through a multi-component reaction is explained. The reactive 1:1

Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening

A novel series of isatin-based inhibitors of β-secretase (BACE-1) have been identified using a virtual high-throughput screening approach. Structure-activity relationship studies revealed structural features important for inhibition. Docking studies suggest these inhibitors may bind within the BACE-1 active site through H-bonding interactions involving the catalytic aspartate residues.